Eris Lifesciences Limited has informed the Exchange regarding Board meeting held on February 13, 2026.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eris Lifesciences' board approved its Q3 FY26 results on February 13, 2026. Consolidated revenue from operations grew about 10% year-on-year to Rs 807.47 crores, while consolidated net profit jumped roughly 25% to Rs 108.83 crores, with basic EPS of Rs 7.32 versus Rs 6.15 a year ago. For the nine-month period (April–December 2025), consolidated revenue rose to Rs 2,378.38 crores and net profit surged about 35% to Rs 368.40 crores (EPS Rs 24.81 vs Rs 18.99). The company booked a one-time exceptional charge of Rs 17.24 crores (consolidated) and Rs 14.67 crores (standalone) due to higher gratuity and leave liabilities from India's new Labour Codes effective November 21, 2025. Standalone Q3 numbers were weak at Rs 315.29 crores revenue and Rs 3.09 crores net profit, reflecting inter-company dynamics. Auditor Walker Chandiok & Co LLP issued an unmodified review opinion.
Strong consolidated profit growth of about 25% YoY in Q3 and 35% for 9M FY26 is a positive signal for shareholders, though the exceptional Labour Code charge trims headline profit. The recent buyout of the remaining 30% stake in Swiss Parenterals, making it wholly-owned, removes minority interest leakage going forward and should be earnings-accretive for owners.